Journal article
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial
Abstract
Oral anticoagulation is the mainstay of therapy for stroke prevention in patients with atrial fibrillation (AF). Vitamin K antagonists such as warfarin have many drawbacks that reduce their uptake, safety and effectiveness. The ROCKET AF trial compared rivaroxaban (20 mg/day; 15 mg/day in patients with creatinine clearance 30-49 ml/min) with dose-adjusted warfarin (international normalized ratio 2-3) in 14,264 patients with AF and a prior …
Authors
Paikin JS; Manolakos JJ; Eikelboom JW
Journal
Expert Review of Cardiovascular Therapy, Vol. 10, No. 8, pp. 965–972
Publisher
Taylor & Francis
Publication Date
August 2012
DOI
10.1586/erc.12.91
ISSN
1477-9072